Carbimazole differs from propylthiouracil in that:
A. It is dose to dose less potent
B. It has a shorter plasma half life
C. It does not produce an active metabolite
D. It does not inhibit peripheral conversion of
thyroxine to triiodothyronine
A. It is dose to dose less potent
B. It has a shorter plasma half life
C. It does not produce an active metabolite
D. It does not inhibit peripheral conversion of
thyroxine to triiodothyronine